Confronting Pancreatic Cancer

COMMENTS to the CMS

The Lorenzen Cancer Foundation has joined with the public interest law firm Washington Legal Foundation and others to urge the Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (“CMS”) to terminate national reviews at issue (especially for Eloxatin, Camptosar, Bexxar and Zevalin) and clarify that the Medicare program will reimburse for “off-label” uses of these cancer medicines.

Eloxatin (oxaliplatin) in combination with gemcitabine has been utilized in the “off-label” treatment of pancreatic adenocarcinoma.

And the Pfizer agent Camptosar (as well as Eloxatin) are well represented in a number of clinical trials related to pancreatic cancer. There are examples of both of these agents in the Pancreatica clinical trials database: http://www.pancreatica.org/Search.cfm.

Dale O’Brien, MD, MPH
Medical Director
Lorenzen Cancer Foundation

Ellen Pansky, esq.
Director of Public Policy
Lorenzen Cancer Foundation

Aaron Stoertz
Media Relations
Lorenzen Cancer Foundation

Full Text of COMMENTS to the CMS (in PDF format): please click [Here]

Full Text of the Press Release: please click [Here]

Link to the Washington Legal Foundation: please click [Here]

Home | In The News | Links | Donations
FAQ | Clinical Trials Registry | Research Resources | About Us

webmaster

©2000-2009 Pancreatica.org - All Rights Reserved
www.pancreatica.org

	COMMENTS to the CMS The Lorenzen Cancer Foundation has joined with the public interest law firm Washington Legal Foundation and others to urge the Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (“CMS”) to terminate national reviews at issue (especially for Eloxatin, Camptosar, Bexxar and Zevalin) and clarify that the Medicare program will reimburse for “off-label” uses of these cancer medicines. Eloxatin (oxaliplatin) in combination with gemcitabine has been utilized in the “off-label” treatment of pancreatic adenocarcinoma. And the Pfizer agent Camptosar (as well as Eloxatin) are well represented in a number of clinical trials related to pancreatic cancer. There are examples of both of these agents in the Pancreatica clinical trials database: http://www.pancreatica.org/Search.cfm. Dale O’Brien, MD, MPH Medical Director Lorenzen Cancer Foundation Ellen Pansky, esq. Director of Public Policy Lorenzen Cancer Foundation Aaron Stoertz Media Relations Lorenzen Cancer Foundation Full Text of COMMENTS to the CMS (in PDF format): please click [Here] Full Text of the Press Release: please click [Here] Link to the Washington Legal Foundation: please click [Here]


	Home \| In The News \| Links \| Donations FAQ \| Clinical Trials Registry \| Research Resources \| About Us

	webmaster

	©2000-2009 Pancreatica.org - All Rights Reserved www.pancreatica.org